Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
12 2021
Historique:
received: 27 01 2021
accepted: 11 05 2021
pubmed: 19 6 2021
medline: 27 1 2022
entrez: 18 6 2021
Statut: epublish

Résumé

We present a field evaluation of the diagnostic accuracy of Xpert MTB/RIF ("Xpert") and Xpert MTB/RIF Ultra ("Ultra") using two cohorts in a high tuberculosis/HIV burden setting in Southern Mozambique. Single respiratory specimens from symptomatic adults accessing healthcare services (passive case finding (PCF) cohort) and from household and community close contacts (active case finding (ACF) cohort) were tested by smear microscopy, culture, Xpert and Ultra. Liquid and solid culture served as a composite reference standard. We explored the impact of trace results on specificity 1419 and 252 participants were enrolled in the PCF and ACF cohorts, respectively. For the PCF cohort, Ultra showed higher sensitivity than Xpert overall (0.95 (95% CI 0.90-0.98) These results add evidence on the improved sensitivity of Ultra and support its use in different case finding scenarios.

Identifiants

pubmed: 34140293
pii: 13993003.00257-2021
doi: 10.1183/13993003.00257-2021
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIBIB NIH HHS
ID : U54 EB027049
Pays : United States

Informations de copyright

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.

Déclaration de conflit d'intérêts

Conflict of interest: B. Saavedra has nothing to disclose. Conflict of interest: E. Mambuque has nothing to disclose. Conflict of interest: D. Nguenha has nothing to disclose. Conflict of interest: N. Gomes has nothing to disclose. Conflict of interest: S. Munguambe has nothing to disclose. Conflict of interest: J.I. Garcia has nothing to disclose. Conflict of interest: S. Izco has nothing to disclose. Conflict of interest: S. Acacio has nothing to disclose. Conflict of interest: A. Murias-Closas has nothing to disclose. Conflict of interest: M. Cossa has nothing to disclose. Conflict of interest: I. Losada has nothing to disclose. Conflict of interest: H. Pernas-Pardavila has nothing to disclose. Conflict of interest: L. Oliveras has nothing to disclose. Conflict of interest: G. Theron has nothing to disclose. Conflict of interest: A.L. García-Basteiro has nothing to disclose.

Auteurs

Belén Saavedra (B)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Edson Mambuque (E)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Dinis Nguenha (D)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Neide Gomes (N)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Shilzia Munguambe (S)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Juan Ignacio García (JI)

TB Group, Population Health Programme, Texas Biomedical Research Institute, San Antonio, TX, USA.

Santiago Izco (S)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Sozinho Acacio (S)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Adrià Murias-Closas (A)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Marta Cossa (M)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Irene Losada (I)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Hadrián Pernas-Pardavila (H)

Infectious Diseases, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.

Laura Oliveras (L)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Agència de Salut Pública de Barcelona, Barcelona, Spain.
Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain.

Grant Theron (G)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Alberto L García-Basteiro (AL)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique alberto.garcia-basteiro@manhica.net.
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH